Is racecadotril safe to use during pregnancy?

Racecadotril Safety in Pregnancy

Racecadotril should be avoided during pregnancy due to insufficient safety data in pregnant women, despite its proven efficacy and safety profile in treating acute diarrhea in non-pregnant populations.

Evidence Assessment

The provided evidence contains no specific guidelines or FDA labeling information regarding racecadotril use in pregnancy. The drug label references 1 actually describe carvedilol (a beta-blocker), not racecadotril, which appears to be a documentation error in the evidence provided.

Available Safety Data

Human Pregnancy Data

• No adequate and well-controlled studies exist in pregnant women for racecadotril
• One guideline mentions racecadotril had "a controlled study in pregnancy" showing safety 2, but this reference is from 2001 and provides no details about outcomes, trimester exposure, or sample size
• The research evidence [3-4,5] extensively documents racecadotril's efficacy and safety in adults and children with acute diarrhea, but none address pregnancy-specific outcomes

Mechanism and Theoretical Considerations

Racecadotril is an enkephalinase inhibitor that:

• Works peripherally by preventing degradation of endogenous enkephalins 3, 6
• Does not cross the blood-brain barrier 6
• Reduces intestinal hypersecretion without affecting gastrointestinal motility or transit time 6, 7

Clinical Recommendation Framework

When acute diarrhea occurs in pregnancy:

1. First-line treatment: Oral rehydration solution alone

   • Cornerstone of therapy regardless of pregnancy status
   • No fetal risk

2. If pharmacologic therapy is required:

   • Consider the general principle that drugs should only be used in pregnancy "if potential benefits justify the potential risk to the fetus" 8
   • Loperamide has more extensive pregnancy safety data than racecadotril 2

3. Risk-benefit assessment:

   • Maternal dehydration from severe diarrhea poses documented fetal risks
   • Unknown fetal risks from racecadotril must be weighed against known maternal/fetal risks of untreated severe diarrhea
   • In emergency situations where maternal health is threatened, drugs without pregnancy data should not be withheld 8

Key Caveats

• The absence of reported adverse effects does not equal proven safety
• Racecadotril's peripheral action and inability to cross the blood-brain barrier 6 may theoretically reduce fetal exposure, but placental transfer data are unavailable
• If inadvertent first-trimester exposure occurs, pregnancy termination is not automatically indicated—close monitoring is appropriate 8

Consult specialized teratology resources (such as www.embryotox.de mentioned in 8) for the most current pregnancy-specific guidance on racecadotril before prescribing.